Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01515306 · ClinicalTrials.gov registry record · Phase 2

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

A Phase 2 study of Malignant Solid Tumor, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
6
Study locations

NCT01515306 is a Phase 2 study of Malignant Solid Tumor that has completed, run by Eli Lilly and Company. The registered enrollment target is 48 participants, below the 162-participant average among 8 other Malignant Solid Tumor trials with a reported enrollment target (70% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01515306, a Phase 2 study of Malignant Solid Tumor, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to investigate whether there are no clinically significant pharmacokinetic effects of concomitant ramucirumab (IMC-1121B) on paclitaxel by investigating the pharmacokinetics (PK) of each in participants with advanced malignant solid tumors. Part A of this study will investigate the potential of concomitant ramucirumab (IMC-1121B) to affect the pharmacokinetics of paclitaxel. Part B of this study will investigate the pharmacokinetics of ramucirumab (IMC-1121B) as monotherapy.

Conditions Studied

Malignant Solid Tumor

Interventions

  • DRUG paclitaxel
  • BIOLOGICAL ramucirumab (IMC-1121B)

Study Locations (6)

Michigan

  • ImClone Investigational Site - Ann Arbor
  • ImClone Investigational Site - Detroit

New Jersey

  • ImClone Investigational Site - New Brunswick

Ohio

  • ImClone Investigational Site - Cleveland

Pennsylvania

  • ImClone Investigational Site - Philadelphia

Washington

  • ImClone Investigational Site - Seattle

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2012-07-19
Est. Completion 2021-02-22
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01515306

The ClinicalTrials.gov registry entry for NCT01515306 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 8 other Malignant Solid Tumor trials with a reported enrollment target (70% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malignant Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.

NCT01515306 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Michigan, New Jersey, Ohio.

Frequently Asked Questions

What is clinical trial NCT01515306 about?

NCT01515306 is a clinical study titled "A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors". The purpose of this study is to investigate whether there are no clinically significant pharmacokinetic effects of concomitant ramucirumab (IMC-1121B) on paclitaxel by investigating the pharmacokinetics (PK) of each in participants with advanced malignant solid tumors. Part A of this study will inv...

What is the current status of trial NCT01515306?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2012-07-19. Estimated completion is 2021-02-22.

What conditions does trial NCT01515306 study?

This clinical trial studies the following conditions: Malignant Solid Tumor.

What interventions are being tested in trial NCT01515306?

The interventions under investigation include: paclitaxel (DRUG), ramucirumab (IMC-1121B) (BIOLOGICAL).

Who is sponsoring clinical trial NCT01515306?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01515306 being conducted?

This trial has 6 study locations across Michigan, New Jersey, Ohio, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Malignant Solid Tumor

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.